Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel in Recurrent or Persistent Uterine Leiomyosarcoma
NCT00003054Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Aug 1997
- Primary completion
- Jul 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in uterine leiomyosarcoma (uLMS), sponsored by GOG Foundation. Primary endpoints: Objective Response Rate and Adverse Events. Started Aug 1997; status: terminated.
02
Drugs
paclitaxel
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT00003054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003054.